Start the conversation
It was the very first stock we recommended on the very first day we published Private Briefing back on Aug. 11, 2011.
We kept re-recommending the stock after that - and it kept going up in price.
The stock has surged as much as 663%.
And a respected stock researcher just rated this biotech as a "Buy."Let me tell you all about it...
This is premium content for Private Briefing subscribers only.